According to a research report, Morgan Stanley has updated its risk-return assessment for TRAD CHI MED (00570). Following the company's preliminary 2025 results announcement, and based on expectations of lower sales and gross margin, the firm has reduced its profit forecasts for 2026 to 2030 by 5% to 12%. Consequently, the target price and bearish scenario valuation have been lowered by 7%; the target price has been cut from HK$1.5 to HK$1.4, with an "Underweight" rating maintained.